LINC00426 may reshape the tumor immune microenvironment, which is positively associated with Th cell differentiation, cytokine signaling pathways, and multiple immune markers, including cytotoxic markers, co-inhibitory and co-stimulatory molecules (i.e., PD1, CTLA4, HAVCR2, TIGIT, FOXP3, and ICOS), and chemokine receptors and ligands (i.e., CXCR3/6, CXCL9/13, CCL4/5/7/19, and CCR7) (Wang et al., 2021b). The gene discussed is ICOS; the disease is neoplasm.